Global Sorafenib Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sorafenib Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Sorafenib is a kinase inhibitor drug approved for the treatment of primary kidney cancer
Sorafenib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Sorafenib market is projected to reach US$ 786.5 million in 2029, increasing from US$ 915 million in 2022, with the CAGR of -2.2% during the period of 2024 to 2029. Demand from Kidney Cancer and Liver Cancer are the major drivers for the industry.
Sorafenib is a targeted therapy used in the treatment of various cancers, including liver, kidney, and thyroid cancer. Factors driving market growth include the increasing incidence of these cancers, advancements in cancer treatment options, and the effectiveness of sorafenib in improving patient outcomes. The market is highly competitive, with several pharmaceutical companies manufacturing and marketing sorafenib. However, challenges such as high treatment costs, potential side effects, and the emergence of alternative therapies may hinder market growth. Nonetheless, the sorafenib market holds promising opportunities, driven by the growing global burden of cancer and the continuous research and development efforts to enhance the therapeutic potential of sorafenib.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sorafenib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bayer
Natco Pharma
Cipla
Mylan
Segment by Type
Patented Drugs
Generic Drugs
Kidney Cancer
Liver Cancer
Thyroid Cancer
Other
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Sorafenib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Sorafenib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Sorafenib industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Sorafenib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Sorafenib introduction, etc. Sorafenib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Sorafenib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Sorafenib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Sorafenib market is projected to reach US$ 786.5 million in 2029, increasing from US$ 915 million in 2022, with the CAGR of -2.2% during the period of 2024 to 2029. Demand from Kidney Cancer and Liver Cancer are the major drivers for the industry.
Sorafenib is a targeted therapy used in the treatment of various cancers, including liver, kidney, and thyroid cancer. Factors driving market growth include the increasing incidence of these cancers, advancements in cancer treatment options, and the effectiveness of sorafenib in improving patient outcomes. The market is highly competitive, with several pharmaceutical companies manufacturing and marketing sorafenib. However, challenges such as high treatment costs, potential side effects, and the emergence of alternative therapies may hinder market growth. Nonetheless, the sorafenib market holds promising opportunities, driven by the growing global burden of cancer and the continuous research and development efforts to enhance the therapeutic potential of sorafenib.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sorafenib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bayer
Natco Pharma
Cipla
Mylan
Segment by Type
Patented Drugs
Generic Drugs
Segment by Application
Kidney Cancer
Liver Cancer
Thyroid Cancer
Other
Segment by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Sorafenib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Sorafenib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Sorafenib industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Sorafenib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Sorafenib introduction, etc. Sorafenib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Sorafenib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices